D.E. Shaw & Co’s Kailera Therapeutics KLRA Stock Holding History

D.E. Shaw & Co’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$386K	Buy	+17,500	New	+$385K	﹤0.01%	4296

Other funds holding KLRA

BCI

Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

D.E. Shaw & Co's KLRA Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 17,500 shares worth $386K. The stake represents ﹤0.01% of the portfolio and ranks #4296 among its holdings.

99 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

D.E. Shaw & Co held 17,500 shares of Kailera Therapeutics worth $386K as of Q2 2026.
Kailera Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
Kailera Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4296 holding.
99 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.